Pronota, Molecuence Partner on Stroke Biomarker Deal

Feb 22, 2011

NEW YORK (GenomeWeb News) – German biomarker firm Pronota today announced a deal with Molecuence for the discovery and validation of stroke biomarkers.

Pronota will use its MASStermind protein biomarker platform for the discovery stage of the deal, and its MASSterclass technology for the verification work.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

This Week in Nature

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Its Own Version

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

Just the Train Going By

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

New Technique a 'Go'

The House of Lords in the UK approves a bill to allow mitochondrial donation.

Featured White Papers

Reverse Phase Protein Arrays for Cell Signaling: Using the InnoScan 710-IR scanner improves sensitivity and dynamic range.

Infrared detection decreases nitrocellulose autofluorescence and improves RPPA assays signal‐to‐noise ratio over visible wavelength detection

Mar

05

Featured Webinar

Integrating Metabolomic and Proteomic Profiles for 'Less Impersonal' Medicine

In this live webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.

Main menu